US2011182893A1PendingUtilityA1

Prevention and treatment of amyloidogenic diseases

59
Assignee: SCHENK DALE BPriority: Jun 1, 1999Filed: Feb 23, 2011Published: Jul 28, 2011
Est. expiryJun 1, 2019(expired)· nominal 20-yr term from priority
Inventors:Dale B. Schenk
A61P 37/02A61P 43/00A61P 9/10A61P 3/10A61P 37/00A61P 37/04A61P 7/04A61P 31/00A61P 25/28A61P 3/00A61P 35/00A61P 29/00A61P 17/00A61P 19/02A61P 19/00A61P 1/04A61P 17/06A61K 2039/6037A61K 2039/55572G01N 2800/2814C07K 16/18A61K 2039/55566G01N 2800/2821G01N 33/6896A61K 39/0007A61K 2039/505C07K 2317/77A61K 2039/55505A61K 2039/55577A61K 38/00
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Passive immunotherapy methods for treating a patient having atherosclerosis.

Claims

exact text as granted — not AI-modified
1 - 57 . (canceled) 
     
     
         58 . A method of therapeutically treating atherosclerosis in a patient comprising administering an effective dosage of an antibody or a fragment thereof, which antibody or fragment thereof specifically binds to an amyloid protein, to thereby treat atherosclerosis in the patient. 
     
     
         59 . The method of  claim 58  wherein the patient demonstrates elevated levels of ApoE. 
     
     
         60 . The method of  claim 58  wherein the antibody or fragment thereof specifically binds to an aggregated form of ApoA. 
     
     
         61 . The method of  claim 58  wherein the antibody or fragment thereof specifically binds to both aggregated and dissociated forms of ApoA. 
     
     
         62 . The method of  claim 58  wherein the antibody or fragment thereof is human, chimeric or humanized antibody. 
     
     
         63 . The method of  claim 63 , wherein the isotype of the antibody is human IgG1. 
     
     
         64 . The method of  claim 58  wherein the antibody or fragment thereof is administered in multiple dosages. 
     
     
         65 . The method of  claim 58  wherein the antibody or fragment thereof is administered as a sustained release composition. 
     
     
         66 . A method of reducing risk or delaying onset of atherosclerosis in a patient comprising administering an effective dosage of an antibody or a fragment thereof, which antibody or fragment thereof specifically binds to an amyloid protein, to thereby effect prophylaxis of the atherosclerosis. 
     
     
         67 . The method of  claim 66  wherein the patient demonstrates elevated levels of ApoE. 
     
     
         68 . The method of  claim 66  wherein the antibody or fragment thereof specifically binds to an aggregated form of ApoA. 
     
     
         69 . The method of  claim 66  wherein the antibody or fragment thereof specifically binds to both aggregated and dissociated forms of ApoA. 
     
     
         70 . The method of  claim 66  wherein the antibody or fragment thereof is human, chimeric or humanized antibody. 
     
     
         71 . The method of  claim 70 , wherein the isotype of the antibody is human IgG1. 
     
     
         72 . The method of  claim 66  wherein the antibody or fragment thereof is administered in multiple dosages. 
     
     
         73 . The method of  claim 66  wherein the antibody or fragment thereof is administered as a sustained release composition.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.